Randomized comparison of rotational chemotherapy in high-risk acute lymphoblastic leukaemia of childhood - Follow up after 9 years

European Journal of Pediatrics

Volumn 155, Issue 8, 1996, Pages 640-648

  Janka Schaub, G E ^a   Harms, D ^a   Goebel, U ^b   Graubner, U ^c   Gutjahr, P ^d   Haas, R J ^c   Juergens, H ^b   Spaar, H J ^e   Winkler, K ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^e Prof Hess Kinderklinik   (Germany)

Author keywords

Acute lymphoblastic leukaemia; Childhood; Combination chemotherapy; Rotation of drugs

Indexed keywords

ANTILEUKEMIC AGENT; ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; TENIPOSIDE; TIOGUANINE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; AGE; ARTICLE; CHILD; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; INFANT; INTRATHECAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SURVIVAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; PROGNOSIS; SURVIVAL RATE; TIME FACTORS;

EID: 0030035328     PISSN: 03406199     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004310050459     Document Type: Article

References (34)

1. Bleyer WA (1977) Clinical pharmacology of intrathecal methotrexate. II. An improved dosage regimen derived from age-related pharmacokinetics. Cancer Treat Rep 61: 1419-1425
2. Capizzi RL (1974) Schedule-dependent synergism and antagonism between methotrexate and asparaginase. Biochem Pharmacol 23 [Suppl 2]: 151-161
3. Chessels JM, Bailey CC, Richards S on behalf of the Medical Research Council Working Party on Childhood Leukaemia (1992) MRC UKALL X. The UK protocol for childhood ALL: 1985-1990. Leukemia 6 [Suppl 2]: 157-161
4. Clavell LA, Gelber RD, Cohen HJ, Hitchcock-Bryan S, Cassady JR, Tarbell NJ, Blattner SR, Tantravahi R, Leavitt P, Sallan SE (1986) Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. N Engl J Med 315: 657-663
5. DeVita VT (1983) The relationship between tumor mass and resistance to chemotherapy. Cancer 51: 1209-1220
6. Drescher U, Stehn M, Harms D, Kapaun P, Goertitz I, Kohlschuetter A, Janka-Schaub GE (1994) Differing length of asparagine depletion in children receiving treatment with E. coli (C-ASP)- or Erwinia-asparaginase (E-ASP) (abstract). Klin Paediatr 206: 352
7. Gobrecht O, Goebel U, Graubner U, Gutjahr P, Schoeck V, Spaar HJ, Janka-Schaub GE fuer die COALL-Studiengruppe (1992) Einfluß von Dosisintensitaet und therapiebedinger Leukozytopenie in der Intensivtherapie auf die Prognose bei akuter lymphatischer Leukaemie im Kindesalter. Klin Paediatr 204: 230-235
8. Goldie JH, Coldman AJ (1979) A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63: 1727-1733
9. Goldie JH, Coldman AJ, Gudauskas GA (1982) Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treat Rep 66: 439-449
10. Gustafsson G, Garwicz S, Hertz H, Johanesson G, Jonmundsson G, Moe PJ, Salmi T, Seip M, Siimes MA, Yssing M, Ahstroem L (1987) A population-based study of childhood acute lymphoblastic leukemia diagnosed from July 1981 through June 1985 in the five nordic countries. Acta Paediatr Scand 76: 781-788
11. Haghbin M, Murphy L, Tan CC, Clarkson BD, Thaler HT, Passe S, Burchenal J (1980) A long-term clinical follow-up of children with acute lymphoblastic leukemia treated with intensive chemotherapy regimens. Cancer 46: 241-252
12. Harms D, Schwamborn D, Spaar HJ, Graubner U, Schoeck V, Winkler K, Janka GE for the COALL Study Group (1994) Daunorubicin-induced cell kill with 1-hour vs. 24-hour infusions: randomized comparison in newly diagnosed children with acute lymphoblastic leukemia. (abstract) Med Pediatr Oncol 23: 197
13. Henze G, Langermann HJ, Gadner H, Schellong G, Welte K, Riehm H (1981) Ergebnisse der Studie BFM 76/79 zur Behandlung der akuten lymphoblastischen Leukaemie bei Kindern und Jugendlichen. Klin Paediatr 193: 145-154
14. Hryniuk WM (1987) Average relative dose intensity and the impact on design of clinical trials. Semin Oncol 14: 65-74
15. Janka-Schaub GE, Winkler K, Goebel U, Graubner U, Gutjahr P, Haas RJ, Juergens H, Spaar J for the COALL Study Group (1988) Rapidly rotating combination chemotherapy in childhood acute lymphoblastic leukemia: preliminary results of a randomized comparison with conventional treatment. Leukemia 2 [Suppl]: 73S-78S
16. Janka-Schaub GE, Goebel U, Graubner U, Haas RJ, Juergens H, Spaar HJ, Winkler K (1990) Improved prognosis for childhood acute lymphocytic leukemia with very high white blood cell count (>100/nl) with rotation of non-cross-resistant drug combinations. Haematol Bloodtransfus 33: 489-493
17. Janka-Schaub GE, Stuehrk H, Kortuem B, Graubner U, Juergens H Spaar HJ, Schoeck V, Dohrn B, Bahr R, Winkler K fuer die COALL-Studiengruppe (1991) Initiales Ansprechen auf die Therapie als wichtigster prognostischer Faktor bei der akuten lymphoblastischen Leukaemie im Kindesalter. Klin Paediatr 203: 231-235
18. Juergens H, Janka G, Ibrahim M, Tonen C, Winkler K, Goebel U (1992) Prognostic significance of exposure to intermediate-dose methotrexate in children with standard risk ALL: the COALL 82/85 experience. Haematol Blood-transfus 34: 338-352
19. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481
20. Land VJ, Shuster JJ, Crist WM, Ravindranath Y, Harris MB, Krance RA, Pinkel D, Pullen DJ (1994) Comparison of two schedules of intermediate-dose methotrexate and cytarabine consolidation therapy for childhood B-precursor cell acute lymphoblastic leukemia: A Pediatric Oncology Group Study. J Clin Oncol 12: 1939-1945
21. Lauer SJ, Camitta BM, Leventhal BG, Mahoney DH Jr, Shuster JJ, Adair S, Casper JT, Civin CI, Graham M, Kiefer G, Pullen J, Steuber CP, Kamen B (1993) Intensive alternating drug pairs for treatment of high-risk childhood acute lymphoblastic leukemia. Cancer 71: 2854-2861
22. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP (1991) Late cardiac effects of doxorubicin in childhood lymphoblastic leukemia. N Engl J Med 324: 808-815
23. Meadows AT, Gordon J, Massari DJ, Littman P, Fergusson J, Moss K (1981) Declines in IQ scores and cognitive dysfunctions in children with acute lymphocytic leukaemia treated with cranial irradiation. Lancet II: 1015-1018
24. Miller DR, Coccia PF, Bleyer WA, Lukens JN, Siegel SE, Sather HN, Hammond GD (1989) Early response to induction therapy as a predictor of disease-free survival and late recurrence of childhood acute lymphoblastic leukemia: a report from the Childrens Cancer Study Group. J Clin Oncol 7: 1807-1815
25. Neglia JP, Meadows AT, Robison LL, Kim TH, Newton WA, Ruymann FB, Sather HN, Hammond GD (1991) Second neoplasms after acute lymphoblastic leukemia in childhood. N Engl J Med 325: 1330-1336
26. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG (1977) Design and analysis of randomized clincial trials requiring prolonged observation of each patient. Br J Cancer 35: 1-39
27. Riehm H, Reiter A, Schrappe M, Berthold F, Dopfer R, Gerein V, Ludwig R, Ritter J, Stollmann B, Henze G (1986) Die Corticosteroidabhaengige Dezimierung der Leukaemiezellzahl im Blut als Prognosefaktor bei der akuten lymphoblastischen Leukaemie im Kindesalter (Therapiestudie ALL-BFM 83). Klin Paediatr 199: 151-160
28. Riehm H, Gadner H, Henze G, Kornhuber B, Lampert F, Niethammer D, Reiter A, Schellong G (1990) Results and significance of six randomized trials in four consecutive ALL-BFM studies. Haematol Bloodtransfus 33: 439-450
29. Rivera GK, Aur RJ, Dahl GV, Pratt CB, Wood A, Avery TL (1980) Combined VM-26 and cytosine arabinoside in treaatment of refractory childhood lymphocytic leukemia. Cancer 45: 1284-1288
30. Rivera GK, Raimondi SC, Hancock ML, Behm FG, Pui CH, Abromowitch M, Mirro J Jr, Ochs JS, Look AT, Williams DL, Murphy SB, Dahl GV, Kalwinsky DK, Evans WE, Kun LE, Simone JV, Crist WM (1991) Improved outcome in childhood acute lymhoblastic leukaemia with reinforced early treatment and rotational combination chemotherapy. Lancet 337: 61-66
31. Sallan SE, Camitta BM, Cassady JR, Nathan DG, Frei E III (1978) Intermittent combination chemotherapy with adriamycin for childhood acute lymphoblastic leukemia: clinical results. Blood 51: 425-433
32. Schorin MA, Blattner S, Gelber RD, Tarbell NJ, Donnelly M, Dalton V, Cohen HJ, Sallan SE (1994) Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber Cancer Institute/Children's Hospital acute lymphoblastic leukemia consortium protocol 85-01. J Clin Oncol 12: 740-747
33. Steinherz PG, Gaynon P, Miller DR, Reaman G, Bleyer A, Finklestein J, Evans RG, Meyers P, Steinhere LJ, Sather H, Hammond D (1986) Improved disease-free survival of children with acute lymphoblastic leukemia at high risk for early relapse with the New York regimen - a new intensive therapy protocol: A report form the Childrens Cancer Study Group. J Clin Oncol 4: 744-752
34. Wells RJ, Feusner J, Devney R, Woods WG, Provisor AJ, Cairo MS, Odom LF, Nachman J, Jones GR, Ettinger LJ, Capizzi RL (1985) Sequential high-dose cytosine arabinoside-asparaginase treatment in advanced childhood leukemia. J Clin Oncol 3: 998-1004